News from Rhythm A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 06, 2014, 11:02 ET Rhythm Presents Positive GI Motility Results for Relamorelin (RM-131) in Phase 2 Chronic Constipation Study

Rhythm announced today the presentation of pharmacodynamic results from a Phase 2 clinical trial with relamorelin (RM-131) for the treatment of...


May 06, 2014, 11:00 ET Rhythm Presents Positive Phase 2 Study Results for Ghrelin Prokinetic Relamorelin (RM-131) in Diabetic Gastroparesis

 Rhythm announced today the presentation of results from a Phase 2 clinical trial assessing the safety and efficacy of relamorelin (RM-131) in...


Sep 24, 2013, 08:00 ET Rhythm Initiates Clinical Trial of RM-493 for Obesity Caused by Genetic Variant

 Rhythm announced today the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor...


Sep 10, 2013, 06:30 ET Rhythm Awarded $1.35 Million from The Michael J. Fox Foundation to Advance Clinical Development of RM-131 for Refractory Constipation in Parkinson's Disease

Rhythm announced today that The Michael J. Fox Foundation for Parkinson's Research (MJFF) has awarded a $1.35 million research grant to Rhythm to...


May 20, 2013, 08:30 ET Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes

Rhythm announced today the results of a second Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic...


May 20, 2013, 08:30 ET Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.

 Rhythm announced today the presentation of results from a new epidemiology study demonstrating a higher prevalence of gastroparesis symptoms...


Apr 16, 2013, 06:30 ET Rhythm Initiates Phase 2 Clinical Trial of Ghrelin Prokinetic RM-131 for Lower GI Functional Disorders

 Rhythm announced today the initiation of an additional Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the...


Jan 04, 2013, 07:00 ET Rhythm Initiates Phase 2 Clinical Trial of RM-493 for Obesity

 Rhythm announced today the initiation of a Phase 2 clinical trial with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for...


Nov 27, 2012, 06:30 ET Rhythm Expands Series B Financing to $33 Million; Adds Pfizer Ventures as an Investor

Rhythm announced today that the company has raised an additional $8 million to complete a $33 million Series B financing. The additional $8 million...


Oct 22, 2012, 07:48 ET Rhythm Announces Positive Phase 1 Results for Ghrelin Prokinetic RM-131

Rhythm announced today the results of two Phase 1 clinical trials of RM-131, the company's novel ghrelin agonist for the treatment of diabetic...


Jun 13, 2012, 08:00 ET Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics

 Rhythm announced today that it has raised $25 million in a Series B financing round. All existing investors participated in the...


Jun 06, 2012, 12:19 ET Rhythm Initiates Phase 2 Clinical Trial of Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis

 Rhythm announced today the initiation of a Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the treatment of...


May 22, 2012, 11:00 ET Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis

Rhythm announced today the results of a Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic...


Nov 30, 2011, 07:00 ET Rhythm Names Lex Van der Ploeg Chief Scientific Officer

 Rhythm announced today that Lex Van der Ploeg, PhD, has joined the company as Chief Scientific Officer. Dr. Van der Ploeg brings to...


Nov 09, 2011, 07:30 ET Rhythm Names Keith M. Gottesdiener Chief Executive Officer

Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today the appointment of Keith M. Gottesdiener,...


Jul 26, 2011, 07:30 ET Rhythm Expands Scientific Advisory Board for Clinical Programs in Metabolic Diseases

Rhythm announced today three appointments to its Scientific Advisory Board to work with the company on its clinical development programs in...


May 09, 2011, 08:00 ET Rhythm's RM-131 Restores GI Function as a Potent Ghrelin Prokinetic

Rhythm announced today results demonstrating that RM-131, the company's novel ghrelin agonist, was highly effective in restoring normal gastric...


Sep 08, 2010, 08:00 ET Rhythm Closes $40 Million Series A Financing

Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that it has completed its Series A...